Details for Patent: 8,853,176
✉ Email this page to a colleague
Title: | Methods for treating HCV |
Abstract: | The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. |
Inventor(s): | Bernstein; Barry M. (Mequon, WI), Menon; Rajeev M. (Buffalo Grove, IL), Khatri; Amit (Waukegan, IL), Mensing; Sven (Mannheim, DE), Dutta; Sandeep (Gurnee, IL), Cohen; Daniel E. (Wilmette, IL), Podsadecki; Thomas J. (Chicago, IL), Brun; Scott C. (Green Oaks, IL), Awni; Walid M. (Green Oaks, IL), Dumas; Emily O. (Libertyville, IL), Klein; Cheri E. (Northbrook, IL) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Filing Date: | Oct 19, 2012 |
Application Number: | 13/656,024 |
Claims: | 1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) and ribavirin to an HCV patient, wherein said treatment does not include administration of interferon to said patient, and said treatment lasts for 12 weeks, wherein said at least two DAAs comprise (1) Compound 1 or a pharmaceutically acceptable salt thereof and (2) Compound 4 or a pharmaceutically acceptable salt thereof, wherein Compound 1 or the salt thereof is co-administered with ritonavir, and wherein said patient is a treatment-naive patient infected with HCV genotype 2. 2. The method of claim 1, wherein said Compound 1 or salt thereof is administered once daily, and said Compound 4 or salt thereof is administered once daily. 3. The method of claim 1, wherein said Compound 1 or salt thereof, and said Compound 2 or salt thereof, are co-formulated in a single composition and administered once daily. |